Early Cancer Recurrence Detection: A Tumor-Informed Approach

natera
4/22/21, 5:00 PM
America/Los_Angeles (PT) -7

Description

Molecular residual disease (MRD) detection is emerging as a powerful and non-invasive tool for improving the management of cancer in the post-operative treatment setting. Using circulating tumor DNA can help accurately identify MRD sooner than current standard of care tools but choosing the right assay with proven performance and high sensitivity is key.

Join us for this live Clinical OMICs webinar for a dynamic discussion with our esteemed guests Dr. Gregory Botta from UC San Diego and Dr. Angel Rodriguez from Natera, who will review the value of a tumor informed approach to optimize patient management in the adjuvant treatment setting.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Panelists:

Gregory Botta, MD, PhD
Medical Oncologist
UC San Diego

Angel Rodriguez, MD
Medical Director, Oncology
Natera

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Early Cancer Recurrence Detection: A Tumor-Informed Approach

Inglês

 

Speakers

Gregory Botta, Angel Rodriguez

 

Link to the Event

Banner to the Event

Early Cancer Recurrence Detection: A Tumor-Informed Approach